Option Care Health (OPCH) Q1 2026 earnings review
Growth Wall Hit: Chronic Inflammatory Cliff Forces Guidance Slashes
Option Care Health's growth narrative has hit a severe wall. After posting 13% revenue growth in FY25, top-line growth essentially stalled in 26Q1, rising just 1.3% year-over-year. The primary culprit is a massive miscalculation of the Chronic Inflammatory (CID) and Stelara biosimilar headwind. Management had confidently guided for a $25M-$35M gross profit hit for the year; they have now dramatically revised that to a $55M headwind. Consequently, full-year revenue and operating cash flow guidance were slashed. However, management curiously maintained their Adjusted EBITDA guidance, implying aggressive cost controls will be deployed to offset the top-line destruction.
🐂 Bull Case
Acute therapies continue to post high-single-digit growth, and the IG/neuro portfolio demonstrated solid growth despite the catastrophic performance in the CID segment.
Maintaining the Adjusted EBITDA guidance of $480M-$505M despite slicing roughly $175M off the midpoint of the revenue guidance shows management expects to find significant operational efficiencies or favorable mix shifts to protect margins.
🐻 Bear Case
Just one quarter ago, management 'proactively quantified' the Stelara/CID headwind as a 400bps revenue drag and $25M-$35M GP hit. Updating this to a 600bps drag and $55M GP hit just months later severely damages management's forecasting credibility.
Total revenue growth has been decelerating for four consecutive quarters, dropping from 16.3% in 25Q1 to 1.3% today. The Chronic segment actually flipped to negative growth in the quarter.
⚖️ Verdict: 🔴
Bearish. A sudden and severe downward revision to the core headwind the company faces (Stelara/CID) completely unwinds the 'confident and execution-focused' narrative sold to investors at the end of 2025. The top-line deceleration is sharp and alarming.
Key Themes
Catastrophic Revision of the CID/Stelara Headwind
The defining theme of the quarter is the explosive revision of the Chronic Inflammatory (CID) portfolio headwind. Management initially guided for a 400bps revenue headwind and a $25M-$35M gross profit hit for 2026. This has been suddenly revised to a ~600bps revenue headwind and an approximate $55M gross profit hit. This single forecasting failure dragged the entire Chronic segment into negative YoY growth and forced massive cuts to the full-year top-line outlook.
Acute Segment Growth Decelerating
Throughout 2025, Option Care Health enjoyed mid-teens growth in the Acute segment, fueled heavily by capturing market share from competitor exits. As predicted, this benefit is now lapsing. Acute growth decelerated to 'high single digit' growth in 26Q1. While healthy on an absolute basis, it is no longer strong enough to mask the severe declines in the Chronic portfolio.
Aggressive Margin Defense Required
With the revenue guide slashed but Adjusted EBITDA maintained, Option Care Health will have to rely heavily on structural efficiencies. Management will need to lean heavily on the site-of-care shift—transitioning patients to their infusion clinics—and automated technologies (like AI claims processing) to extract enough operating leverage to hit their $480M-$505M EBITDA target.
Cash Generation Slowdown
First-quarter operating cash flow was deeply negative (-$12.1 million) and worse than the prior year (-$7.2 million). While Q1 is seasonally the weakest for cash flow due to benefit resets and working capital build, the company lowered its full-year cash flow expectation from 'at least $340 million' down to 'at least $320 million,' signaling weaker underlying cash conversion.
Capital Allocation Shifts
Despite a newly expanded $1.0B share repurchase authorization announced in January, the company bought back only $17.5 million of stock in Q1 (compared to $100M in the same quarter last year). Concurrently, they expanded their revolving credit facility from $400M to $850M, indicating a potential preparation for M&A activity or simply shoring up liquidity.
Other KPIs
Reversing into a decline. Down 6.3% YoY. The collapse in the top line flowed directly to earnings, causing EBITDA margins to compress from 8.39% in 25Q1 down to 7.76% in 26Q1.
Declining. Down 3.0% YoY from $46.7M in 25Q1. Despite the drop in net income, GAAP diluted EPS technically grew from $0.28 to $0.29, entirely manufactured by a lower share count stemming from 2025's aggressive share repurchases.
Guidance
Severely Decelerating. Management slashed the prior guidance of $5.8B-$6.0B. The new midpoint ($5.725B) implies just ~1.3% growth versus FY25, an astonishing drop from the 13% growth achieved last year.
Stable. Surprisingly, management maintained this guidance range despite the massive cut to the revenue outlook. This implies the $55M gross profit hit from the CID portfolio will be entirely offset by extreme SG&A cuts or highly favorable mix shifts.
Decelerating. The guidance floor was lowered from the previous expectation of '$340 million' down to '$320 million,' aligning with the challenging revenue environment and a tough start to the year.
Accelerating sequentially. Management expects a rebound off the Q1 bottom, pointing to seasonal stabilization and potential cost-cutting leverage kicking in during the second quarter.
Key Questions
Forecasting Failure on CID
Just months ago, you confidently stated that the Stelara/CID headwind was manageable and quantified it at $25M-$35M. It has now ballooned to $55M. What structurally changed in the market or your models over the last 60 days to cause such a severe miscalculation?
Bridging the EBITDA Gap
You lowered revenue guidance by roughly $175 million at the midpoint and increased the gross profit headwind expectation by $20M+, yet you held Adjusted EBITDA guidance flat. Specifically, what operating expense lines are being cut to protect this margin?
Pace of Share Repurchases
You expanded your repurchase authorization to $1.0B in January but only bought back $17.5M in Q1, an 80%+ drop from last year's Q1 pace. Is this a signal that management views the stock as less attractive given the new CID headwinds, or are you preserving cash for a specific acquisition?